BioLife Solutions Inc (BLFS) CFO Greef Roderick De Sells 10,000 Shares

Share on StockTwits

BioLife Solutions Inc (NASDAQ:BLFS) CFO Greef Roderick De sold 10,000 shares of BioLife Solutions stock in a transaction that occurred on Wednesday, October 17th. The shares were sold at an average price of $12.95, for a total transaction of $129,500.00. Following the sale, the chief financial officer now owns 24,583 shares in the company, valued at approximately $318,349.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Greef Roderick De also recently made the following trade(s):

  • On Wednesday, September 19th, Greef Roderick De sold 10,000 shares of BioLife Solutions stock. The shares were sold at an average price of $17.22, for a total transaction of $172,200.00.
  • On Thursday, August 16th, Greef Roderick De sold 10,000 shares of BioLife Solutions stock. The shares were sold at an average price of $19.10, for a total transaction of $191,000.00.

BLFS stock opened at $12.41 on Friday. BioLife Solutions Inc has a twelve month low of $4.63 and a twelve month high of $26.35. The company has a market cap of $209.56 million, a PE ratio of -59.10 and a beta of 1.51.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings results on Thursday, August 9th. The medical equipment provider reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.01. BioLife Solutions had a net margin of 1.76% and a return on equity of 2.24%. The business had revenue of $5.18 million during the quarter, compared to the consensus estimate of $5.20 million. Research analysts expect that BioLife Solutions Inc will post 0.14 EPS for the current fiscal year.

A number of analysts have recently issued reports on the stock. B. Riley set a $22.00 price objective on shares of BioLife Solutions and gave the company a “buy” rating in a research note on Wednesday, October 3rd. ValuEngine downgraded shares of BioLife Solutions from a “strong-buy” rating to a “buy” rating in a research report on Thursday, September 27th. BidaskClub downgraded shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Saturday, September 22nd. TheStreet raised shares of BioLife Solutions from a “d” rating to a “c-” rating in a research report on Tuesday, September 11th. Finally, Maxim Group reissued a “buy” rating and set a $26.00 price target on shares of BioLife Solutions in a research report on Wednesday, September 5th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $22.00.

Several hedge funds have recently added to or reduced their stakes in BLFS. Millennium Management LLC grew its position in shares of BioLife Solutions by 32.3% during the first quarter. Millennium Management LLC now owns 241,470 shares of the medical equipment provider’s stock worth $1,234,000 after buying an additional 58,920 shares in the last quarter. Bank of Montreal Can acquired a new stake in shares of BioLife Solutions during the second quarter worth approximately $114,000. Essex Investment Management Co. LLC grew its position in shares of BioLife Solutions by 29.4% during the second quarter. Essex Investment Management Co. LLC now owns 295,728 shares of the medical equipment provider’s stock worth $3,374,000 after buying an additional 67,182 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in shares of BioLife Solutions during the second quarter worth approximately $569,000. Finally, BNP Paribas Arbitrage SA acquired a new position in BioLife Solutions in the second quarter worth $799,000. 27.70% of the stock is owned by institutional investors and hedge funds.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death.

See Also: Asset Allocation Models, Which is Right For You?

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Realty Income  Upgraded to “Hold” at Citigroup
Realty Income Upgraded to “Hold” at Citigroup
Meridian Bancorp Inc  to Issue Quarterly Dividend of $0.07 on  January 2nd
Meridian Bancorp Inc to Issue Quarterly Dividend of $0.07 on January 2nd
Devon Energy Corp  To Go Ex-Dividend on December 13th
Devon Energy Corp To Go Ex-Dividend on December 13th
Analysts Set $20.60 Target Price for Bain Capital Specialty Finance Inc
Analysts Set $20.60 Target Price for Bain Capital Specialty Finance Inc
WhiteHorse Finance Inc  Announces $0.36 Quarterly Dividend
WhiteHorse Finance Inc Announces $0.36 Quarterly Dividend
Laurion Capital Management LP Takes $738,000 Position in Sally Beauty Holdings, Inc.
Laurion Capital Management LP Takes $738,000 Position in Sally Beauty Holdings, Inc.


© 2006-2018 Ticker Report